1 Result(s)

Article

Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib

Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors (PPI) or histamine-2 r...

Chia-Han Lee, Mei-Chiou Shen, Ming-Ju Tsai, Jung-San Chang… in Scientific Reports (2022)